Anavex Life Sciences Announces Grant Of U.S. Patent Covering Blarcamesine For Treatment Of Insomnia Or Anxiety
Portfolio Pulse from Benzinga Newsdesk
Anavex Life Sciences Corp. has been granted a U.S. patent for ANAVEX®2-73 (blarcamesine) for treating insomnia, anxiety, or agitation. The patent, expected to last until at least 2037, covers various dosage forms and complements another patent lasting until 2038. The economic burden of insomnia and anxiety in the U.S. is significant, with costs exceeding $100 billion and $46.4 billion respectively. The patent strengthens Anavex's portfolio for treating CNS disorders, including Alzheimer's and Parkinson's diseases.
November 22, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Anavex Life Sciences has been granted a U.S. patent for ANAVEX®2-73, potentially extending the commercial viability of its leading drug candidate until at least 2037. This could enhance the company's market position in treating CNS disorders.
The grant of a new patent typically provides a company with extended market exclusivity, which can protect its revenue potential from competitors. Given the significant economic burden of insomnia and anxiety, and the patent's coverage of various dosage forms, this could be a substantial positive development for Anavex. It may lead to increased investor confidence and a potential rise in stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100